Radiology

Healthcare Leader Kim Tzoumakas Appointed To Transparent Health Marketplace Board of Directors

Retrieved on: 
Friday, October 9, 2020
Radiology, Practice Management, Insurance, Physical therapy, Managed care, Health, Professional services, Other Health, Healthcare industry

Transparent Health Marketplace, Inc. (THM), a transformative healthcare technology company, today announced the appointment of Kim Tzoumakas to its board of directors.

Key Points: 
  • Transparent Health Marketplace, Inc. (THM), a transformative healthcare technology company, today announced the appointment of Kim Tzoumakas to its board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20201009005065/en/
    Healthcare Leader Kim Tzoumakas Appointed To Transparent Health Marketplace Board of Directors (Photo: Business Wire)
    "We are pleased to welcome Kim to our board, said Jim Mayhall, president of Transparent Health Marketplace.
  • Ms. Tzoumakas is a seasoned healthcare executive and board member, with over 20 years of leadership expertise.
  • Transparent Health Marketplace (THM) operates a digital marketplace connecting payors and providers of healthcare services in an open platform featuring market-driven pricing.

LabCorp and HealthEC Launch Transformative Oncology Care Module

Retrieved on: 
Friday, October 9, 2020
Oncology, Medical Supplies, Health, Hospitals, General Health, Radiology, Articles, Burlington, North Carolina, LabCorp, Health care, HealthEC, LabCorp

LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and HealthEC, LLC, a leading provider of population health management solutions, today announced the launch of LabCorps Care Intelligence Oncology Module (Oncology Care Module).

Key Points: 
  • LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and HealthEC, LLC, a leading provider of population health management solutions, today announced the launch of LabCorps Care Intelligence Oncology Module (Oncology Care Module).
  • Available exclusively through LabCorp, the single-platform solution connects claims and clinical systems using the LabCorp Care Intelligence application, powered by HealthEC.
  • View the full release here: https://www.businesswire.com/news/home/20201009005231/en/
    LabCorps Oncology Care Module helps oncology practices measure performance against critical quality and cost benchmarks, including value-based care objectives.
  • As part of LabCorps Care Intelligence application, the Oncology Care Module integrates securely and seamlessly with electronic health records and other practice management tools and systems.

Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030

Retrieved on: 
Thursday, October 8, 2020
Medicine, Medicinal radiochemistry, Clinical medicine, Physical sciences, Medical physics, Medical imaging, Neuroimaging, Radiology, Single-photon emission computed tomography, Nuclear medicine, Emission computed tomography, Positron emission tomography

Presently, a variety of diagnostic and therapeutic techniques are based on the use of such substances, commonly referred to as radiopharmaceuticals.

Key Points: 
  • Presently, a variety of diagnostic and therapeutic techniques are based on the use of such substances, commonly referred to as radiopharmaceuticals.
  • Typically, diagnostic tests, involving radiopharmaceuticals, are performed using highly specialized imaging solutions, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET).
  • Over the years, medical research teams across the world have gradually tapped into the vast potential of radiopharmaceuticals and nuclear medicines.
  • The 'Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030' report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals.

Lantheus Holdings Announces Presentations at the 33rd Annual European Association of Nuclear Medicine (EANM) Virtual Congress

Retrieved on: 
Thursday, October 8, 2020
Oncology, Medical devices, Health, Radiology, Pharmaceutical, Biotechnology, Spanish Empire, Billerica, Massachusetts, North Billerica station, PUERTO RICO, Geography of Massachusetts, Massachusetts counties

Details on the presentations are included below.

Key Points: 

The Medical Device Innovation Consortium (MDIC) Announces Case for Quality Collaborative Community with FDA Participation

Retrieved on: 
Wednesday, October 7, 2020
Health, Medical devices, Surgery, Other Health, Other Science, Radiology, Science, Food and Drug Administration, FDA Center for Devices and Radiological Health, Medical device, Health

The Medical Device Innovation Consortium (MDIC) announced today that the U.S. Food and Drug Administrations (FDA) Center for Devices and Radiological Health (CDRH) will participate in its Case for Quality Collaborative Community (CfQcc) initiative .

Key Points: 
  • The Medical Device Innovation Consortium (MDIC) announced today that the U.S. Food and Drug Administrations (FDA) Center for Devices and Radiological Health (CDRH) will participate in its Case for Quality Collaborative Community (CfQcc) initiative .
  • Todays announcement reflects the agencys commitment to collaborative communities and builds upon existing efforts to help advance medical device quality and safety to achieve better patient outcomes.
  • In 2019, MDICs National Evaluation System for health Technologies Coordinating Center (NESTcc) Collaborative Community was named one of the first collaborative communities with FDA participation.
  • Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle.

Breast Biopsy Market by Product, by Type, Guidance, and Liquid Biopsy - Global Forecasts to 2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 7, 2020
Radiology, Health, Oncology, Medical devices, Clinical medicine, Medicine, Medical specialties, Breast surgery, Cancer screening, RTT, Breast biopsy, Biopsy, Fine-needle aspiration, Liquid biopsy, Mammography, Breast cancer

The "Breast Biopsy Market by Product (Needles, Tables, Assay Kit), by Type (Needle Biopsy (CNB, FNAB, VAB), Liquid Biopsy (CTC, ctDNA)), Guidance (Image-Guided (Mammography, Ultrasound, MRI), Liquid Biopsy (NGS, PCR, Microarray-based)) - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Breast Biopsy Market by Product (Needles, Tables, Assay Kit), by Type (Needle Biopsy (CNB, FNAB, VAB), Liquid Biopsy (CTC, ctDNA)), Guidance (Image-Guided (Mammography, Ultrasound, MRI), Liquid Biopsy (NGS, PCR, Microarray-based)) - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.
  • Based on product, the breast biopsy market is segmented into biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and other products.
  • Based on type, the breast biopsy market is segmented into needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy.
  • In 2019, the needle breast biopsy held a major share of the breast biopsy market.

Polarean Imaging Plc (“Polarean” or the “Company”) NDA Submission

Retrieved on: 
Wednesday, October 7, 2020
Radiology, Health, Medical devices, Health, Food and Drug Administration, Pharmaceutical industry, Clinical research, Design of experiments, Clinical trial, Medical imaging, Magnetic resonance imaging

The submission of the NDA follows the Companys successful completion of two Phase III clinical trials (the Clinical Trials) which demonstrated effective measurement of regional lung ventilation.

Key Points: 
  • The submission of the NDA follows the Companys successful completion of two Phase III clinical trials (the Clinical Trials) which demonstrated effective measurement of regional lung ventilation.
  • The polarised 129Xenon is administered as an inhaled gas that is given to patients in a 10 second breath-hold MRI procedure.
  • Commenting on the submission, Richard Hullihen, CEO of Polarean, said: The NDA submission of 129Xenon gas MRI as a drug-device combination represents another key regulatory milestone for our Company.
  • The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

GenesisCare Acquires Ten New ExacTrac Dynamic Systems for Advanced Cancer Treatment Following FDA Clearance

Retrieved on: 
Wednesday, October 7, 2020
Oncology, Medical devices, Health, FDA, Surgery, Radiology, Medicine, Clinical medicine, Medical specialties, Neurosurgery, Radiobiology, Radiosurgery, Stereotactic surgery, Radiation therapy, Therapy, Oncology, Draft:Surface Guided Radiation Therapy, Mount Miriam Cancer Hospital, Brainlab, 21st Century Oncology, GenesisCare

This follows GenesisCare s acquisition of major integrated cancer care provider, 21st Century Oncology , increasing access to advanced cancer care for patients across US communities.

Key Points: 
  • This follows GenesisCare s acquisition of major integrated cancer care provider, 21st Century Oncology , increasing access to advanced cancer care for patients across US communities.
  • ExacTrac Dynamic will allow GenesisCare physicians to deliver stereotactic radiosurgery, a non-invasive form of radiation therapy which delivers precisely targeted radiation in fewer high-dose treatments than traditional therapies.
  • ExacTrac Dynamic systems have already been rolled out in Australia and the UK, providing patients access to the latest advancements in radiation therapy, including stereotactic radiosurgery and tattoo-free treatment.
  • Building upon the first generation ExacTrac X-Ray, the new ExacTrac Dynamic system expands clinical workflows beyond traditional stereotactic capabilities with new surface-guided and thermal technology.

Global Radiotherapy Equipment Market and Technology Report 2020: Market is Anticipated to Reach $11 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 6, 2020
Radiology, Health, Medical devices

The "Global Radiotherapy Equipment - Market and Technology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Radiotherapy Equipment - Market and Technology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global market for radiotherapy equipment is expected to account for a value of USD 7 Billion in 2020 and it is anticipated to reach USD 11 Billion by 2028.
  • The CAGR for this market is estimated to be 6% during the forecast period.
  • The report is aimed at:
    Insights based on drivers, restraints, and challenges and their impacts on the global market have been mentioned in this report.

Insights on the Dental Radiology Equipment Global Market to 2027 - Featuring Midmark, Planmeca & Vatech Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, October 5, 2020
Radiology, Health, Dental, Business, Articles, Companies, Business intelligence, General Electric, RCA, Schenectady, New York, Thomas Edison, Analytics

The "Dental Radiology Equipment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dental Radiology Equipment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 182-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • This segment currently accounts for a 27.6% share of the global Dental Radiology Equipment market.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.1 Billion by the year 2027.